TLIS
Income statement / Annual
Last year (2023), Talis Biomedical Corporation's total revenue was $412,000.00,
a decrease of 88.72% from the previous year.
In 2023, Talis Biomedical Corporation's net income was -$62.01 M.
See Talis Biomedical Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$412,000.00
|
$3.65 M
|
$0.00
|
$10.94 M
|
$3.98 M
|
$2.39 M
|
| Cost of Revenue |
$41,000.00 |
$8.39 M |
$2.62 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$371,000.00 |
-$4.74 M |
-$2.62 M |
$10.94 M |
$3.98 M |
$2.39 M |
| Gross Profit Ratio |
0.9 |
-1.3 |
0 |
1 |
1 |
1 |
| Research and Development
Expenses |
$40.69 M
|
$70.83 M
|
$157.59 M
|
$89.02 M
|
$23.81 M
|
$18.39 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.21 M
|
$40.73 M
|
$42.42 M
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
| Other Expenses |
-$1.72 M |
-$1.16 M |
-$8.19 M |
-$10.94 M |
-$3.98 M |
$0.00 |
| Operating Expenses |
$67.19 M |
$110.40 M |
$191.82 M |
$91.18 M |
$26.70 M |
$21.43 M |
| Cost And Expenses |
$67.23 M |
$118.79 M |
$191.82 M |
$91.18 M |
$26.70 M |
$21.43 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$54,000.00 |
$42,000.00 |
$93,000.00 |
| Interest Expense |
$0.00 |
-$2.13 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$770,000.00
|
$11.60 M
|
$2.62 M
|
$1.37 M
|
$726,000.00
|
$647,000.00
|
| EBITDA |
-$66.05 M
|
-$106.31 M
|
-$191.82 M
|
-$90.42 M
|
-$25.97 M
|
-$20.78 M
|
| EBITDA Ratio |
-160.3 |
-31.53 |
0 |
-8.27 |
-6.53 |
-8.7 |
| Operating Income Ratio
|
-162.17
|
-31.53
|
0
|
-8.34
|
-6.71
|
-8.97
|
| Total Other
Income/Expenses Net |
$4.81 M
|
$2.13 M
|
-$220,000.00
|
$54,000.00
|
-$775,000.00
|
$93,000.00
|
| Income Before Tax |
-$62.01 M |
-$113.01 M |
-$192.04 M |
-$91.13 M |
-$27.47 M |
-$21.34 M |
| Income Before Tax Ratio
|
-150.5
|
-30.95
|
0
|
-8.33
|
-6.91
|
-8.93
|
| Income Tax Expense |
$0.00 |
-$2.13 M |
-$1.58 M |
-$54,000.00 |
-$42,000.00 |
$93,000.00 |
| Net Income |
-$62.01 M |
-$110.89 M |
-$190.46 M |
-$91.08 M |
-$27.43 M |
-$21.34 M |
| Net Income Ratio |
-150.5 |
-30.36 |
0 |
-8.33 |
-6.9 |
-8.93 |
| EPS |
-34.12 |
-62.45 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
| EPS Diluted |
-34.12 |
-62.45 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
| Weighted Average Shares
Out |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290,000.00
|
$150,000.00
|
$150,420.00
|
| Weighted Average Shares
Out Diluted |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290,000.00
|
$150,000.00
|
$150,420.00
|
| Link |
|
|
|
|
|
|
